Peel Hunt restated their hold rating on shares of Assura (LON:AGR) in a research report released on Tuesday morning, ThisIsMoney.Co.Uk reports.
Other equities analysts have also issued research reports about the company. Jefferies Financial Group restated a buy rating on shares of Assura in a research note on Friday, December 13th. JPMorgan Chase & Co. raised their price objective on Assura from GBX 79 ($1.04) to GBX 81 ($1.07) and gave the stock an overweight rating in a research note on Thursday, January 16th. Liberum Capital raised their price objective on Assura from GBX 76 ($1.00) to GBX 80 ($1.05) and gave the stock a hold rating in a research note on Monday, January 27th. Barclays initiated coverage on Assura in a research note on Tuesday, December 3rd. They set an overweight rating and a GBX 81 ($1.07) price objective on the stock. Finally, Berenberg Bank started coverage on Assura in a research note on Friday, November 29th. They set a hold rating and a GBX 75 ($0.99) price objective on the stock. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of GBX 76.50 ($1.01).
Assura stock opened at GBX 83.50 ($1.10) on Tuesday. The stock’s fifty day moving average price is GBX 77.91 and its two-hundred day moving average price is GBX 73.42. Assura has a one year low of GBX 56.20 ($0.74) and a one year high of GBX 82 ($1.08). The company has a debt-to-equity ratio of 58.74, a current ratio of 0.79 and a quick ratio of 0.76. The firm has a market cap of $2.02 billion and a PE ratio of 24.56.
Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high-quality patient care in the community.
Further Reading: What is a Buy-Side Analyst?
Receive News & Ratings for Assura Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assura and related companies with MarketBeat.com's FREE daily email newsletter.